Alnylam Pharmaceuticals, Inc. (LON:0HD2)
452.83
+0.93 (0.21%)
At close: Aug 28, 2025
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $773.69M USD in the quarter ending June 30, 2025, with 17.26% growth. This brings the company's revenue in the last twelve months to $2.46B, up 5.01% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$2.46B
Revenue Growth
+5.01%
P/S Ratio
24.59
Revenue / Employee
$1.10M
Employees
2,230
Market Cap
44.20B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Oxford Nanopore Technologies | 183.19M |
Alnylam Pharmaceuticals News
- 2 days ago - Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam - Seeking Alpha
- 2 days ago - Scenic Enters License and Research Agreement with Alnylam - GlobeNewsWire
- 6 days ago - A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics - Benzinga
- 15 days ago - How Is The Market Feeling About Alnylam Pharmaceuticals? - Benzinga
- 15 days ago - Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
- 17 days ago - Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - Business Wire
- 23 days ago - Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 24 days ago - This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga